← Back to all media

Reducing risk through expertise, diversification and a proven investment strategy

Biotechnology is a high-growth sector so it’s understandably alluring for many investors. Many, however, are put off by the perception that it is risky. Success in drug trials can lead to a company doubling its market cap overnight, but failure can lead to capitulation. The swings from fortune to failure can be brutal. So how can investors reap the benefits of the anticipated growth in the biotech market without unacceptably high risks?

Published on 30th September 2019



The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.

An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.

The material on this website is intended to be viewed only by persons resident in the UK.

The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.

No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.

The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).

I do not accept →